Big mon­ey: Flag­ship's uber-plat­form play Laronde rakes in $440M to chase pro­gram­ma­ble 'eR­NA'

With the suc­cess of Mod­er­na, par­ent com­pa­ny Flag­ship Pi­o­neer­ing has be­come the moth­er­ship for even more au­da­cious next-gen plat­form plays. In­vestors like what they see, and now they’ve opened the vault to a par­tic­u­lar­ly bold Flag­ship start­up work­ing on ring-shaped RNA it thinks could be the fu­ture of drug­mak­ing.

Laronde has closed a $440 mil­lion Se­ries B — one of the largest ever fundrais­ing rounds of its type — to pur­sue a pro­gram­ma­ble RNA plat­form the biotech has pre­vi­ous­ly said could churn out 100 mar­ket­ed drugs or drug pro­grams in 10 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER